Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study

Autor: Tatyana N. Sokolova, Tatyana I. Solov'eva, Svetlana N. Aleksakhina, Grigorii A. Janus, Alla Goryainova, Mark I. Gluzman, Rashida V. Orlova, Anastasiya I. Stukan, Ruslan A. Zukov, Alena V. Zyuzyukina, Yulia N. Murunova, Aleksandr V. Sultanbaev, Elena N. Vorobeva, Leonid M. Mikhaevich, Victoria N. Pyliv, Anna N. Lysenko, Zarema K. Khachmamuk, Andrey E. Kozlov, Sergey Y. Bakharev, Shahen G. Parsyan, Elena I. Rossokha, Leri D. Osidze, Irina S. Shumskaya, Anna V. Agaeva, Tatiana A. Kasmynina, Veronika V. Klimenko, Kamila T. Akhmetgareeva, Almira A. Vakhitova, Madina D. Chakhkieva, Vadim N. Dmitriev, Yana I. Bakshun, Alexey E. Vasilyev, Dunya D. Gasimly, Nadezhda A. Kravchenko, Dmitriy A. Maksimov, Alfia I. Nesterova, Ineza O. Sharvashidze, Christina H. Gadzaova, Galina G. Rakhmankulova, Zaur M. Khamgokov, Irina K. Amirkhanova, Ludmila V. Bembeeva, Vladimir I. Vladimirov, Oleg L. Petrenko, Natalia G. Ruskova, Ekaterina L. Serikova, Ksenia S. Subbotina, Svetlana A. Tkachenko, Victor L. Chang, Sanal P. Erdniev, Victoria S. Barbara, Anna V. Vasilevskaya, Yulia V. Mikheeva, Nataliya O. Popova, Ekaterina P. Startseva, Anastasia V. Fateeva, Denis Y. Yukalchuk, Anna A. Grechkina, Khedi S. Musaeva, Svetlana V. Odintsova, Alena S. Stel'makh, Petimat I. Khabibulaeva, Alina G. Khlobystina, Kseniya A. Shvaiko, Elena A. Basova, Irina A. Bogomolova, Marina B. Bolieva, Viktor E. Goldberg, Marianna V. Kibisheva, Konstantin V. Menshikov, Dmitrii V. Ryazanov, Mariya L. Stepanova, Yana A. Udalova, Aleksandr V. Shkradyuk, Yana S. Chapko, Anna A. Shchukina, Idris M. Khabriev, Dmitrii V. Kirtbaya, Alexey M. Degtyarev, Aleksandr A. Epkhiev, Yana A. Tyugina, Mirza A. Murachuev, Aleksandr V. Togo, Aglaya G. Ievleva, Evgenii N. Imyanitov

Publikováno v: Современная онкология, Vol 24, Iss 1, Pp 12-23 (2022)

Background. By 2020, breast cancer (BC) has become the most frequent malignancy in the world. The most common type of BC is HR+/HER2-negative cancer,2540% of which harbors PIK3CA mutations that affect the catalytic subunit of the PI3K protein. PIK3CA

Externí odkaz: https://doaj.org/article/ac2dc051d6cd4d1686520ce6a60f66af